- Approval Id
- 61da976b9bef25f5
- Drug Name
- AROMASIN TABLET 25MG
- Product Name
- AROMASIN TABLET 25MG
- Approval Number
- SIN11398P
- Approval Date
- 2000-09-20
- Registrant
- PFIZER PRIVATE LIMITED
- Licence Holder
- PFIZER PRIVATE LIMITED
- Drug Type
- Therapeutic
- Forensic Classification
- PRESCRIPTION ONLY MEDICINES
- Dosage Form
- TABLET, SUGAR COATED
- Dosage
- <p><strong>4.2. Posology and Method of Administration</strong></p>
<p><u>Adult and Elderly Patients</u></p>
<p>The recommended dose of exemestane is one 25 mg tablet to be taken once daily, preferably after a meal.</p>
<p>In patients with early breast cancer, treatment with exemestane should continue until completion of five years of combined sequential adjuvant hormonal therapy (tamoxifen followed by exemestane), or earlier if tumour relapse occurs.</p>
<p>In patients with advanced breast cancer, treatment with exemestane should continue until tumor progression is evident.</p>
<p><u>Hepatic or Renal Insufficiency</u></p>
<p>No dose adjustments are required for patients with hepatic or renal insufficiency.</p>
<p><u>Children</u></p>
<p>Not recommended for use in children.</p>
- Route Of Administration
- ORAL
- Indication Info
- <p><strong>4.1. Therapeutic Indications</strong></p>
<p>Exemestane is indicated for the adjuvant treatment of post-menopausal women with estrogen-receptor positive invasive early breast cancer, following 2–3 years of initial adjuvant tamoxifen therapy.</p>
<p>Exemestane is indicated for the treatment of advanced breast cancer in women with natural or induced post-menopausal status whose disease has progressed following anti-estrogen therapy.</p>
- Contraindications
- <p><strong>4.3. Contraindications</strong></p>
<p>Exemestane is contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients.</p>
- Atc Code
- L02BG06
- Atc Item Name
- exemestane
- Pharma Manufacturer Name
- PFIZER PRIVATE LIMITED
- Company Detail Path
- /organization/pfizer-private-limited
